Altitude Life Science Ventures (ALSV)
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Altitude Life Science Ventures (ALSV).
Key people at Altitude Life Science Ventures (ALSV).
Altitude Life Science Ventures (ALSV) is a venture capital firm specializing in early-stage investments in life science companies operating in markets with significant demand and growth potential. Their investment focus spans a broad range of life science sectors including therapeutics, diagnostics, gene editing, AI-driven therapeutics, autonomous science, medical devices, dermatology, drug delivery platforms, industrial chemical reactions, and DNA sequencing. ALSV’s mission centers on backing high-quality teams to build defensible, long-term businesses by leveraging proprietary technologies rooted in biology and chemistry. Their investment philosophy emphasizes deep due diligence, particularly around intellectual property (IP) strategy, to maximize and preserve the value of portfolio companies as they mature. This approach supports startups in establishing competitive advantages, preserving product opportunities, and complementing R&D and business development efforts, thereby positively impacting the life science startup ecosystem by fostering innovation and sustainable growth[1][2][4][6].
Founded in 2006 in Durango, Colorado, by Steve Johnson and Dave Maki, Altitude Life Science Ventures has evolved into a specialized investor in life sciences, with a base in Kirkland, Washington. The firm has developed a differentiated investment strategy grounded in extensive experience with IP strategic planning, which distinguishes it from many other venture capital firms. Over time, ALSV has expanded its focus from traditional prescription drugs to a wider array of commercial applications of proprietary life science technologies. The firm has raised multiple funds, including the Altitude Life Science Ventures Fund III, and has built a portfolio that includes notable companies such as Omniome, Nuvation Bio, Beam Therapeutics, and UNITY Biotechnology. ALSV has also achieved several successful exits, including Vir Biotechnology and Receptos, underscoring its ability to identify and nurture promising ventures[2][3][6].
Altitude Life Science Ventures operates at the intersection of several transformative trends in biotechnology and life sciences, including gene editing, AI-driven therapeutics, and advanced diagnostics. The timing of their investments aligns with rapid scientific advances and growing market demand for innovative healthcare solutions. By focusing on proprietary technologies and robust IP strategies, ALSV helps startups navigate competitive pressures and regulatory complexities, thereby accelerating the commercialization of breakthrough therapies and technologies. Their influence extends beyond capital provision to shaping the strategic direction of emerging companies, contributing to the broader ecosystem of life science innovation and commercialization[1][2].
Looking ahead, Altitude Life Science Ventures is well-positioned to capitalize on ongoing advancements in life sciences, particularly in areas like AI-enabled drug discovery, gene editing, and precision medicine. As the life science sector continues to expand and evolve, ALSV’s emphasis on IP strategy and early-stage support will likely enhance its ability to identify disruptive technologies and scale successful companies. Future trends such as autonomous science and integrated diagnostics could further shape their investment focus. ALSV’s continued success will depend on maintaining its differentiated approach and expanding its network to support portfolio companies through increasingly complex development and commercialization pathways[1][2][6].
Key people at Altitude Life Science Ventures (ALSV).
